The effect of L-carnitine in critically ill children admitted to PICU

The Effect of L-Carnitine Supplementation on Some Inflammatory Biomarkers in Critically Ill Children in the Pediatric Intensive Care Unit (PICU): A Triple-Blind, Randomized Controlled Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221206056734N2

Enrollment

Registered

2025-03-07

Start date

2025-02-03

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically ill children admitted to the PICU.

Interventions

Intervention 1: Intervention group: 18 critically ill children admitted to the PICU will receive 50 to 100 mg/kg of liquid oral L-carnitine, produced by Pars Behrouzan Jam Company, along with tube fee

Eligibility

Sex/Gender

All

Age

1 Months to 12 Years

Inclusion criteria

Inclusion criteria: The age range of one month to 12 years. Critically Ill children expected to stay in the PICU for more than 2 to 3 days Legal guardian's consent.

Exclusion criteria

Exclusion criteria: Having liver or kidney diseases that contraindicate L-carnitine use. Children undergoing hemodialysis Children undergoing chemotherapy NPO patients who cannot start enteral nutrition

Design outcomes

Primary

Measure	Time frame
Serum C-Reactive Protein (CRP). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum ESR. Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum Total Antioxidant Capacity (TAC). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum Malondialdehyde (MDA). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum neutrophil to lymphocyte ratio (NLR). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum monocyte to lymphocyte ratio (MLR). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum platelet-to-lymphocyte ratio (PLR). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.	—

Measure

Time frame

Serum C-Reactive Protein (CRP). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum ESR. Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum Total Antioxidant Capacity (TAC). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum Malondialdehyde (MDA). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum neutrophil to lymphocyte ratio (NLR). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum monocyte to lymphocyte ratio (MLR). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum platelet-to-lymphocyte ratio (PLR). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Behrooz

Tabriz University of Medical Sciences

mm.behrooz@gmail.com+98 41 3159 5050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026